The Service Line
Every dialysis clinic in the country will give up about $3 a treatment on January 1 so that the smallest clinics can be paid more. The Centers for Medicare and Medicaid Services (CMS) final 2027 payment rule for end-stage renal disease (ESRD) facilities raises the low-volume payment adjustment threshold from 4,000 to 8,000 treatments and expands it from two tiers to six. The change is budget neutral, so CMS says it trims the base rate by about 1.1 percent, roughly $3, for everyone. Clinics with fewer than 3,000 median treatments over the last three cost reporting years get the largest adjuster, and clinics at 7,000 to 7,999 get the smallest. The attestation deadline for payment year 2027 is extended to December 31, 2026. So what: the middle of the market, clinics above 8,000 treatments, funds the bottom of it. Check your own three-year median now. Confidence: High on the policy, Medium on the dollar effect per clinic, which depends on your tier.
Reimbursement
The headline base rate is $297.52, but $12.85 of it is phosphate binders moving into the bundle. The same CMS fact sheet shows the rate up $15.81 from $281.71, below the $299.55 CMS proposed in June. CMS projects total payments up about 2.7 percent, to $7.0 billion across roughly 7,600 facilities, and the market basket update is 1.9 percent. The home and self-dialysis training add-on rises from $95.60 to $138.00 and, for the first time, can be paid during the first four months of dialysis. So what: the binder add-on is now permanent base-rate money rather than a separate payment, and home programs are the clear winner. The June proposed rule had the rate about $2 higher. Confidence: High.
Nephrologists lose 2.31 percent on the 2027 fee schedule, and the remote monitoring crackdown got a two-year reprieve. The CMS physician fee schedule final rule fact sheet sets the conversion factor at $32.63 for most clinicians, down from $33.40, because the one-year 2.5 percent increase expired. Clinicians who qualify through an advanced alternative payment model get a $32.95 factor, and participants in a Shared Savings Program accountable care organization (ACO) or the LEAD Model get a 32 percent visit modifier, double the 16 percent everyone else gets. CMS delayed to January 1, 2029 the rule that would pay for remote patient monitoring only when practice-employed staff perform it, which matters for chronic kidney disease programs that lean on outsourced vendors. The initiating-visit requirement still starts January 1, 2027. So what: the modifier applies to office visits, not the monthly dialysis capitation codes 90951 to 90970, so the upside sits in stage 3 and 4 kidney disease clinics. Confidence: High on the factors, Medium on how the modifier maps to nephrology claims.
Enforcement
Six dialysis centers and their parent group are paying about $2 million over federal pandemic relief money. The OIG enforcement notice dated October 27 says the SNG Dialysis Centers, six limited partnerships, are alleged to have violated the False Claims Act in claims for Provider Relief Fund payments, with the U.S. Attorney’s Office for the District of Massachusetts as the dateline. Sankar Nephrology Group, the majority owner, will guarantee the settlement amount. This is an allegation resolved without an admission. So what: pandemic-era grants are still being audited, and an owner guaranty is now a standard term. Confidence: High on the settlement, Low on the specific allegations, which the notice does not detail. We covered the settlement when it broke. The window produced no new vascular access or medical directorship case.
Who’s Buying
DaVita’s value-based kidney arm earned $4 million last quarter, down from $40 million, while its risk book grew 25 percent. DaVita’s third quarter results release shows Integrated Kidney Care operating income of $4 million on $144 million of revenue, against $40 million in the second quarter. Patients in risk-based arrangements rose to about 80,800 from 64,900, and annualized medical spend under management to about $6.4 billion from $5.8 billion. The company also bought back 594,000 shares for $111 million in the quarter and nudged the low end of its 2026 adjusted operating income guidance up $25 million to $2.175 billion. So what: DaVita is buying scale in risk contracts faster than it is earning on them, and every independent nephrology group weighing a Strive, Monogram, InterWell or Evergreen deal is now negotiating against a chain that will price aggressively to win attribution. This speaks to the vertical’s recurring question of who wins nephrologist alignment. Confidence: High on figures, Low on the cause of the swing, which the release does not explain.
Clinical Policy
Starting in 2027, dialysis facilities must supply phosphate binders to patients with acute kidney injury, and the quality program swaps its calcium measure for a phosphate one. The CMS final rule fact sheet says facilities must provide medically necessary binders to acute kidney injury patients under their direct care. Beginning with payment year 2029, the Facility-Level Percentage of Chronic Hyperphosphatemia in Dialysis Patients measure replaces the hypercalcemia reporting measure, and the bloodstream infection measure moves to a 2023 baseline with new risk adjustment for access type and station count. So what: chronic phosphorus control becomes a scored outcome two years out, which is when binder protocols, dietitian time and lab frequency need to be settled. Confidence: High.
The Operator Metric
Patient care cost per treatment: $280.22 at DaVita in the third quarter, up $2.82 in one quarter. The same DaVita release puts nine-month cost at $279.24 against $271.23 a year earlier, up $8.01, and attributes the quarterly rise mainly to medical supplies. Revenue per treatment was $415.25. Compare that with the 2027 Medicare base rate: after the $12.85 binder fold-in, the change CMS made to the underlying rate is $2.96, and the low-volume change takes about $3 back. Our arithmetic, not CMS’s. So what: costs rose more in nine months at the largest chain than Medicare’s non-binder increase delivers for all of 2027, and commercial and Medicare Advantage mix is what keeps margins whole. Track your own cost per treatment against the $297.52 rate before you sign any 2027 payer or supplier contract. Confidence: Medium, because the bundle now absorbs binder cost that previously sat outside it.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.